Multidisciplinary Care Program to Secure MEdication Therapy for HematoLOgy Patients Receiving Injectable Anticancer Drugs

NCT ID: NCT05350930

Last Updated: 2025-03-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

38 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-09

Study Completion Date

2023-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Several experiences of multidisciplinary care pathways associating oncologists, pharmacists and nurses have been reported for cancer patients, with positive results on medication management safety, reduction of Drug-Related Problems (DRPs), and re-hospitalizations.

This study aims to evaluate the impact of a multidisciplinary city-hospital follow-up program on medication management safety in haematological oncology patients receiving intravenous chemotherapy in onco-haematology. Additional aspects will be evaluated, such as the impact of the follow-up on the city-hospital link, satisfaction of patients and professionals involved in the follow-up and the use of telecare

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chemotherapy Effect G-CHOP Chemotherapy R-CHOP Chemotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

R-CHOP or G-CHOP chemotherapy

Patients with hematological malignancies receiving R-CHOP or G-CHOP chemotherapy

Assessment of patient satisfaction regarding tele-consultation

Intervention Type OTHER

Questionnaire completed following the teleconsultation, if applicable.

Literacy questionnaire

Intervention Type OTHER

Questionnaire completed during hospitalization for the first chemotherapy cycle

Collection of socio-demographic characteristics

Intervention Type OTHER

Questionnaire completed during patient hospitalization for the first chemotherapy cycle

Assessment of patient knowledge on chemotherapy side effects and support medications

Intervention Type OTHER

Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy

Assessment of patient satisfaction on pharmaceutical follow-up

Intervention Type OTHER

Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Assessment of patient satisfaction regarding tele-consultation

Questionnaire completed following the teleconsultation, if applicable.

Intervention Type OTHER

Literacy questionnaire

Questionnaire completed during hospitalization for the first chemotherapy cycle

Intervention Type OTHER

Collection of socio-demographic characteristics

Questionnaire completed during patient hospitalization for the first chemotherapy cycle

Intervention Type OTHER

Assessment of patient knowledge on chemotherapy side effects and support medications

Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy

Intervention Type OTHER

Assessment of patient satisfaction on pharmaceutical follow-up

Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Adult patients aged 18 years or older With hematological malignancy at any stage Initiating R-CHOP or G-CHOP chemotherapy Who do not object to participation in the study and use of collected data

Exclusion Criteria

* Patients already enrolled in a clinical trial evaluating any drug product
* Patients living in an institution
* Patients protected by law

* Adults subject to a legal protection measure (curatorship, guardianship) (article L1121-8 of the CSP)
* Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care and persons admitted to a health or social establishment (article L1121-6 of the CSP)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Lyon Sud - Hospices Civils de lyon

Pierre-Bénite, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

69HCL22_0292

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study in Non Small Cell Lung Cancer
NCT01139775 COMPLETED PHASE1/PHASE2